Systemic pro-inflammatory response following bronchoscopic lung volume reduction using endobronchial valves

Area of Science:

• Pulmonology
• Immunology
• Biomarkers

Background:

• Bronchoscopic lung volume reduction using endobronchial valves (EBV) improves outcomes in severe COPD patients.
• The impact of EBV treatment on systemic inflammation remains poorly understood.

Purpose of the Study:

• To investigate the effect of EBV treatment on the systemic inflammatory cytokine profile in severe COPD patients.

Main Methods:

• A sub-study of the SoLVE trial collected blood samples from 66 patients before and 6 months after EBV or EBV+pulmonary rehabilitation (PR) treatment.
• Assessed 10 inflammatory markers to evaluate changes in cytokine profiles.

Main Results:

• Six months post-treatment, a pro-inflammatory cytokine profile was observed, with increased pro-inflammatory markers and decreased interleukin-10.
• These cytokine changes did not correlate with improvements in lung function or exercise capacity.

Conclusions:

• Successful EBV treatment leads to elevated systemic pro-inflammatory cytokines in COPD patients.
• The observed increase in inflammation was not associated with adverse clinical outcomes, warranting further investigation into its causes.